EPCAM and breast cancer: In breast cancer, N-glycosylation mutations of EpCAM reduce N-linked glycosylation, affecting the EMT [35] and cellular apoptosis by regulating the expression of both anti-apoptotic protein Bcl-2 and the pro-apoptotic proteins Bax and Caspase 3 [93], as well as cell adhesion FAK/Akt/Gsk-3β/β-catenin signaling pathway [94].